Arvinas Inc at Guggenheim Partners Healthcare Talks Oncology Days (Virtual) Transcript
All right. Hello, and welcome. My name is Michael Schmidt. I am one of the biotech analysts at Guggenheim. And it is my great pleasure to welcome Ian Taylor, Chief Scientific Officer of Arvinas. It's a great pleasure to host you, Ian, and thanks for joining us.
My pleasure. Thanks for the invitation.
Questions & Answers
All right, super. So we'll just jump in into Q&A. Ian, Arvinas has obviously been one of the key innovators in the TPD space and also the first company to advance a degrader program into clinical development. One thing that we get asked a lot is -- and now that there's more activity in this category -- how proprietary is the TPD technology, the PROTAC technology, and how high are barriers to entry as we see more and more programs emerge?
Yeah,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |